STOCK TITAN

[8-K] QCR Holdings Inc Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

N2OFF, Inc. (Nasdaq: NITO) has called a 2025 special meeting to seek shareholder approval for four key proposals.

  • Acquisition: N2OFF will buy 100% of Israeli oncology start-up MitoCareX Bio Ltd. by issuing new NITO shares equal to ≈40% of post-close fully diluted shares plus up to another 25% in milestone stock, $700k cash and up to $1.6 m of future-financing proceeds. MitoCareX founders will also receive 5% RSUs and board control of the subsidiary.
  • Reverse split: Board authority to effect a 1-for-2 to 1-for-150 reverse split within 12 months.
  • Warrants: Approval to issue 1,850,000 common shares on exercise of a warrant held by L.I.A. Pure Capital Ltd.
  • Adjournment: Standard authority if more time is needed to solicit votes.

The board unanimously recommends voting FOR all items. If approved, existing holders face substantial dilution, potential additional issuance through milestones and warrants, and the possibility of a large reverse split to maintain Nasdaq compliance. The deal adds an early-stage oncology platform but exposes N2OFF to R&D funding obligations and integration risks. Two N2OFF directors also serve on MitoCareX seller SciSparc’s board, creating related-party considerations.

N2OFF, Inc. (Nasdaq: NITO) ha convocato un'assemblea straordinaria per il 2025 al fine di ottenere l'approvazione degli azionisti su quattro proposte chiave.

  • Acquisizione: N2OFF acquisirà il 100% della startup oncologica israeliana MitoCareX Bio Ltd. emettendo nuove azioni NITO pari a circa il 40% delle azioni completamente diluite post-chiusura, più fino al 25% aggiuntivo in azioni legate a milestone, 700.000 dollari in contanti e fino a 1,6 milioni di dollari provenienti da futuri finanziamenti. I fondatori di MitoCareX riceveranno inoltre il 5% in RSU e il controllo del consiglio della controllata.
  • Split inverso: Autorità al consiglio per effettuare uno split inverso da 1 a 2 fino a 1 a 150 entro 12 mesi.
  • Warrant: Approvazione per emettere 1.850.000 azioni ordinarie all'esercizio di un warrant detenuto da L.I.A. Pure Capital Ltd.
  • Rinvio: Autorità standard nel caso sia necessario più tempo per raccogliere voti.

Il consiglio raccomanda all'unanimità di votare SI su tutti i punti. Se approvate, le azioni esistenti subiranno una diluizione significativa, con possibile ulteriore emissione tramite milestone e warrant, e la possibilità di un ampio split inverso per mantenere la conformità al Nasdaq. L'accordo aggiunge una piattaforma oncologica in fase iniziale, ma espone N2OFF a obblighi di finanziamento per R&S e rischi di integrazione. Due direttori di N2OFF siedono anche nel consiglio di SciSparc, venditore di MitoCareX, creando considerazioni di parti correlate.

N2OFF, Inc. (Nasdaq: NITO) ha convocado una reunión especial para 2025 con el fin de obtener la aprobación de los accionistas para cuatro propuestas clave.

  • Adquisición: N2OFF comprará el 100% de la startup israelí de oncología MitoCareX Bio Ltd. emitiendo nuevas acciones NITO equivalentes a aproximadamente el 40% de las acciones totalmente diluidas después del cierre, además de hasta un 25% adicional en acciones por hitos, $700,000 en efectivo y hasta $1.6 millones de ingresos por financiamiento futuro. Los fundadores de MitoCareX también recibirán un 5% en RSU y el control del consejo de la subsidiaria.
  • Consolidación inversa: Autoridad para la junta para llevar a cabo una consolidación inversa de 1 por 2 hasta 1 por 150 dentro de 12 meses.
  • Warrants: Aprobación para emitir 1,850,000 acciones comunes al ejercer un warrant en poder de L.I.A. Pure Capital Ltd.
  • Aplazamiento: Autoridad estándar si se necesita más tiempo para solicitar votos.

La junta recomienda por unanimidad votar A FAVOR de todos los puntos. Si se aprueba, los accionistas actuales enfrentarán una dilución sustancial, posible emisión adicional mediante hitos y warrants, y la posibilidad de una gran consolidación inversa para mantener el cumplimiento con Nasdaq. El acuerdo agrega una plataforma oncológica en etapa temprana, pero expone a N2OFF a obligaciones de financiamiento en I+D y riesgos de integración. Dos directores de N2OFF también forman parte del consejo de SciSparc, vendedor de MitoCareX, lo que genera consideraciones de partes relacionadas.

N2OFF, Inc. (나스닥: NITO)는 2025년 특별 주주총회를 소집하여 네 가지 주요 안건에 대한 주주 승인을 요청합니다.

  • 인수: N2OFF는 이스라엘의 종양학 스타트업 MitoCareX Bio Ltd.의 100% 지분을 인수하며, 인수 완료 후 완전 희석 주식의 약 40%에 해당하는 신규 NITO 주식과 최대 25%의 마일스톤 주식, 70만 달러 현금, 그리고 최대 160만 달러의 향후 자금 조달 수익을 발행합니다. MitoCareX 창립자들은 5% RSU와 자회사의 이사회 통제권도 받습니다.
  • 역병합: 이사회가 12개월 이내에 1대 2에서 1대 150까지 역병합을 시행할 권한을 부여받습니다.
  • 워런트: L.I.A. Pure Capital Ltd.가 보유한 워런트 행사 시 1,850,000 보통주 발행 승인.
  • 연기: 투표를 더 많이 확보해야 할 경우 표준 연기 권한.

이사회는 모든 안건에 대해 만장일치로 찬성 투표를 권고합니다. 승인될 경우 기존 주주들은 상당한 희석, 마일스톤 및 워런트를 통한 추가 발행 가능성, 그리고 나스닥 상장 유지 위해 대규모 역병합 가능성에 직면하게 됩니다. 이번 거래는 초기 단계의 종양학 플랫폼을 추가하지만, N2OFF는 연구개발 자금 조달 의무와 통합 리스크에 노출됩니다. N2OFF 이사 두 명은 MitoCareX 매도사 SciSparc 이사회에도 참여해 관련 당사자 고려사항이 발생합니다.

N2OFF, Inc. (Nasdaq : NITO) a convoqué une assemblée générale extraordinaire en 2025 pour obtenir l'approbation des actionnaires sur quatre propositions clés.

  • Acquisition : N2OFF achètera 100 % de la start-up israélienne en oncologie MitoCareX Bio Ltd. en émettant de nouvelles actions NITO équivalant à environ 40 % des actions totalement diluées après clôture, plus jusqu'à 25 % supplémentaires en actions liées à des jalons, 700 000 $ en espèces et jusqu'à 1,6 million de dollars provenant de futurs financements. Les fondateurs de MitoCareX recevront également 5 % de RSU et le contrôle du conseil d'administration de la filiale.
  • Regroupement inversé : Pouvoir au conseil d'effectuer un regroupement inversé de 1 pour 2 à 1 pour 150 dans les 12 mois.
  • Bons de souscription : Approbation pour émettre 1 850 000 actions ordinaires lors de l'exercice d'un bon de souscription détenu par L.I.A. Pure Capital Ltd.
  • Ajournement : Pouvoir standard si plus de temps est nécessaire pour solliciter les votes.

Le conseil recommande à l'unanimité de voter POUR tous les points. En cas d'approbation, les actionnaires existants feront face à une dilution importante, à une émission potentielle supplémentaire via des jalons et des bons de souscription, ainsi qu'à la possibilité d'un important regroupement inversé pour maintenir la conformité au Nasdaq. L'accord ajoute une plateforme oncologique en phase précoce mais expose N2OFF à des obligations de financement en R&D et à des risques d'intégration. Deux administrateurs de N2OFF siègent également au conseil de SciSparc, vendeur de MitoCareX, ce qui soulève des considérations de parties liées.

N2OFF, Inc. (Nasdaq: NITO) hat eine außerordentliche Hauptversammlung für 2025 einberufen, um die Zustimmung der Aktionäre zu vier wichtigen Vorschlägen einzuholen.

  • Akquisition: N2OFF wird 100 % des israelischen Onkologie-Start-ups MitoCareX Bio Ltd. erwerben, indem neue NITO-Aktien ausgegeben werden, die ca. 40 % der nach dem Abschluss vollständig verwässerten Aktien entsprechen, plus bis zu weiteren 25 % in Meilenstein-Aktien, 700.000 USD in bar und bis zu 1,6 Mio. USD aus zukünftigen Finanzierungserlösen. Die Gründer von MitoCareX erhalten außerdem 5 % RSUs und die Kontrolle über den Vorstand der Tochtergesellschaft.
  • Reverse Split: Vorstandsvollmacht, innerhalb von 12 Monaten einen Reverse-Split von 1:2 bis 1:150 durchzuführen.
  • Warrants: Genehmigung zur Ausgabe von 1.850.000 Stammaktien bei Ausübung eines Warrants, der von L.I.A. Pure Capital Ltd. gehalten wird.
  • Vertagung: Standardvollmacht, falls mehr Zeit zur Stimmeneinholung benötigt wird.

Der Vorstand empfiehlt einstimmig, allen Punkten ZUZUSTIMMEN. Bei Genehmigung sehen sich bestehende Inhaber einer erheblichen Verwässerung, potenziellen zusätzlichen Emissionen durch Meilensteine und Warrants sowie der Möglichkeit eines großen Reverse Splits zur Einhaltung der Nasdaq-Anforderungen gegenüber. Der Deal erweitert die frühe Onkologie-Plattform, bringt N2OFF jedoch auch Verpflichtungen zur F&E-Finanzierung und Integrationsrisiken. Zwei N2OFF-Direktoren sitzen zudem im Vorstand von SciSparc, dem Verkäufer von MitoCareX, was Interessenkonflikte mit sich bringt.

Positive
  • Diversification into oncology drug discovery via MITOLINE™ platform
  • Potential technological synergies and strengthened management team from MitoCareX
  • Milestone structure ties part of consideration to future performance
Negative
  • Immediate dilution of ≈40% at closing, rising to ≈65% if milestones and warrants are met
  • Large reverse split (up to 1-for-150) signals Nasdaq compliance pressure
  • Ongoing cash obligation to fund MitoCareX R&D beyond initial $1 m
  • Early-stage target risk: no products, limited operating history, accumulated deficit
  • Related-party relationships could create perceived conflicts of interest

Insights

TL;DR: Highly dilutive biotech acquisition; strategic upside but significant execution and funding risk.

The transaction transforms N2OFF from its current scope into an early-stage oncology player, issuing up to 65% of post-close equity (40% at close + 25% milestones) and committing at least $1 m in fresh cash plus ongoing R&D support. While the MITOLINE™ platform could broaden the company’s technology stack, MitoCareX has no revenue, $2.1 m accumulated deficit and funding runway only into Q4-25, meaning N2OFF must raise capital soon—now under more dilutive terms. The optional 1-for-150 reverse split signals concern over Nasdaq bid-price compliance. Shareholders should weigh long-term optionality against near-term dilution, integration complexity and biotech execution risk.

TL;DR: Governance red flags offset by clear disclosure and audit-committee approval.

Two N2OFF directors sit on the board of seller SciSparc and the target’s CSO is related to a N2OFF lender, creating conflicts. Management mitigated this via audit-committee review and full proxy disclosure, but minority shareholders still bear dilution and financing obligations. The capped indemnities, two-year rep & warranty survival and milestone-based earn-outs are standard, yet the 30% cut of future financings to sellers until $1.6 m is paid is unusual and could burden capital raises. Overall impact is neutral: governance process appears adequate, but structural terms favor sellers.

N2OFF, Inc. (Nasdaq: NITO) ha convocato un'assemblea straordinaria per il 2025 al fine di ottenere l'approvazione degli azionisti su quattro proposte chiave.

  • Acquisizione: N2OFF acquisirà il 100% della startup oncologica israeliana MitoCareX Bio Ltd. emettendo nuove azioni NITO pari a circa il 40% delle azioni completamente diluite post-chiusura, più fino al 25% aggiuntivo in azioni legate a milestone, 700.000 dollari in contanti e fino a 1,6 milioni di dollari provenienti da futuri finanziamenti. I fondatori di MitoCareX riceveranno inoltre il 5% in RSU e il controllo del consiglio della controllata.
  • Split inverso: Autorità al consiglio per effettuare uno split inverso da 1 a 2 fino a 1 a 150 entro 12 mesi.
  • Warrant: Approvazione per emettere 1.850.000 azioni ordinarie all'esercizio di un warrant detenuto da L.I.A. Pure Capital Ltd.
  • Rinvio: Autorità standard nel caso sia necessario più tempo per raccogliere voti.

Il consiglio raccomanda all'unanimità di votare SI su tutti i punti. Se approvate, le azioni esistenti subiranno una diluizione significativa, con possibile ulteriore emissione tramite milestone e warrant, e la possibilità di un ampio split inverso per mantenere la conformità al Nasdaq. L'accordo aggiunge una piattaforma oncologica in fase iniziale, ma espone N2OFF a obblighi di finanziamento per R&S e rischi di integrazione. Due direttori di N2OFF siedono anche nel consiglio di SciSparc, venditore di MitoCareX, creando considerazioni di parti correlate.

N2OFF, Inc. (Nasdaq: NITO) ha convocado una reunión especial para 2025 con el fin de obtener la aprobación de los accionistas para cuatro propuestas clave.

  • Adquisición: N2OFF comprará el 100% de la startup israelí de oncología MitoCareX Bio Ltd. emitiendo nuevas acciones NITO equivalentes a aproximadamente el 40% de las acciones totalmente diluidas después del cierre, además de hasta un 25% adicional en acciones por hitos, $700,000 en efectivo y hasta $1.6 millones de ingresos por financiamiento futuro. Los fundadores de MitoCareX también recibirán un 5% en RSU y el control del consejo de la subsidiaria.
  • Consolidación inversa: Autoridad para la junta para llevar a cabo una consolidación inversa de 1 por 2 hasta 1 por 150 dentro de 12 meses.
  • Warrants: Aprobación para emitir 1,850,000 acciones comunes al ejercer un warrant en poder de L.I.A. Pure Capital Ltd.
  • Aplazamiento: Autoridad estándar si se necesita más tiempo para solicitar votos.

La junta recomienda por unanimidad votar A FAVOR de todos los puntos. Si se aprueba, los accionistas actuales enfrentarán una dilución sustancial, posible emisión adicional mediante hitos y warrants, y la posibilidad de una gran consolidación inversa para mantener el cumplimiento con Nasdaq. El acuerdo agrega una plataforma oncológica en etapa temprana, pero expone a N2OFF a obligaciones de financiamiento en I+D y riesgos de integración. Dos directores de N2OFF también forman parte del consejo de SciSparc, vendedor de MitoCareX, lo que genera consideraciones de partes relacionadas.

N2OFF, Inc. (나스닥: NITO)는 2025년 특별 주주총회를 소집하여 네 가지 주요 안건에 대한 주주 승인을 요청합니다.

  • 인수: N2OFF는 이스라엘의 종양학 스타트업 MitoCareX Bio Ltd.의 100% 지분을 인수하며, 인수 완료 후 완전 희석 주식의 약 40%에 해당하는 신규 NITO 주식과 최대 25%의 마일스톤 주식, 70만 달러 현금, 그리고 최대 160만 달러의 향후 자금 조달 수익을 발행합니다. MitoCareX 창립자들은 5% RSU와 자회사의 이사회 통제권도 받습니다.
  • 역병합: 이사회가 12개월 이내에 1대 2에서 1대 150까지 역병합을 시행할 권한을 부여받습니다.
  • 워런트: L.I.A. Pure Capital Ltd.가 보유한 워런트 행사 시 1,850,000 보통주 발행 승인.
  • 연기: 투표를 더 많이 확보해야 할 경우 표준 연기 권한.

이사회는 모든 안건에 대해 만장일치로 찬성 투표를 권고합니다. 승인될 경우 기존 주주들은 상당한 희석, 마일스톤 및 워런트를 통한 추가 발행 가능성, 그리고 나스닥 상장 유지 위해 대규모 역병합 가능성에 직면하게 됩니다. 이번 거래는 초기 단계의 종양학 플랫폼을 추가하지만, N2OFF는 연구개발 자금 조달 의무와 통합 리스크에 노출됩니다. N2OFF 이사 두 명은 MitoCareX 매도사 SciSparc 이사회에도 참여해 관련 당사자 고려사항이 발생합니다.

N2OFF, Inc. (Nasdaq : NITO) a convoqué une assemblée générale extraordinaire en 2025 pour obtenir l'approbation des actionnaires sur quatre propositions clés.

  • Acquisition : N2OFF achètera 100 % de la start-up israélienne en oncologie MitoCareX Bio Ltd. en émettant de nouvelles actions NITO équivalant à environ 40 % des actions totalement diluées après clôture, plus jusqu'à 25 % supplémentaires en actions liées à des jalons, 700 000 $ en espèces et jusqu'à 1,6 million de dollars provenant de futurs financements. Les fondateurs de MitoCareX recevront également 5 % de RSU et le contrôle du conseil d'administration de la filiale.
  • Regroupement inversé : Pouvoir au conseil d'effectuer un regroupement inversé de 1 pour 2 à 1 pour 150 dans les 12 mois.
  • Bons de souscription : Approbation pour émettre 1 850 000 actions ordinaires lors de l'exercice d'un bon de souscription détenu par L.I.A. Pure Capital Ltd.
  • Ajournement : Pouvoir standard si plus de temps est nécessaire pour solliciter les votes.

Le conseil recommande à l'unanimité de voter POUR tous les points. En cas d'approbation, les actionnaires existants feront face à une dilution importante, à une émission potentielle supplémentaire via des jalons et des bons de souscription, ainsi qu'à la possibilité d'un important regroupement inversé pour maintenir la conformité au Nasdaq. L'accord ajoute une plateforme oncologique en phase précoce mais expose N2OFF à des obligations de financement en R&D et à des risques d'intégration. Deux administrateurs de N2OFF siègent également au conseil de SciSparc, vendeur de MitoCareX, ce qui soulève des considérations de parties liées.

N2OFF, Inc. (Nasdaq: NITO) hat eine außerordentliche Hauptversammlung für 2025 einberufen, um die Zustimmung der Aktionäre zu vier wichtigen Vorschlägen einzuholen.

  • Akquisition: N2OFF wird 100 % des israelischen Onkologie-Start-ups MitoCareX Bio Ltd. erwerben, indem neue NITO-Aktien ausgegeben werden, die ca. 40 % der nach dem Abschluss vollständig verwässerten Aktien entsprechen, plus bis zu weiteren 25 % in Meilenstein-Aktien, 700.000 USD in bar und bis zu 1,6 Mio. USD aus zukünftigen Finanzierungserlösen. Die Gründer von MitoCareX erhalten außerdem 5 % RSUs und die Kontrolle über den Vorstand der Tochtergesellschaft.
  • Reverse Split: Vorstandsvollmacht, innerhalb von 12 Monaten einen Reverse-Split von 1:2 bis 1:150 durchzuführen.
  • Warrants: Genehmigung zur Ausgabe von 1.850.000 Stammaktien bei Ausübung eines Warrants, der von L.I.A. Pure Capital Ltd. gehalten wird.
  • Vertagung: Standardvollmacht, falls mehr Zeit zur Stimmeneinholung benötigt wird.

Der Vorstand empfiehlt einstimmig, allen Punkten ZUZUSTIMMEN. Bei Genehmigung sehen sich bestehende Inhaber einer erheblichen Verwässerung, potenziellen zusätzlichen Emissionen durch Meilensteine und Warrants sowie der Möglichkeit eines großen Reverse Splits zur Einhaltung der Nasdaq-Anforderungen gegenüber. Der Deal erweitert die frühe Onkologie-Plattform, bringt N2OFF jedoch auch Verpflichtungen zur F&E-Finanzierung und Integrationsrisiken. Zwei N2OFF-Direktoren sitzen zudem im Vorstand von SciSparc, dem Verkäufer von MitoCareX, was Interessenkonflikte mit sich bringt.

false 0000906465 0000906465 2025-07-25 2025-07-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

 

Form 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event Reported): July 25, 2025

 

QCR Holdings, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware 0-22208 42-1397595
(State or Other Jurisdiction of
Incorporation)
(Commission File Number) (I.R.S. Employer Identification
Number)

 

3551 Seventh Street, Moline, Illinois 61265
(Address of Principal Executive Offices) (Zip Code)

 

(309) 736-3584

(Registrant's telephone number, including area code)

 

N/A
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $1.00 Par Value QCRH The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 8.01.Other Events.

 

Redemption of 5.25% Fixed-to-Floating Rate Subordinated Notes due 2030

 

On July 25, 2025, QCR Holdings, Inc. (the “Company”) issued a notice of full redemption (the “2030 Notice”) pursuant to that certain Additional Paying Agent and Co-Registrar Agreement, dated as of September 22, 2020, between Guaranty Federal Bancshares, Inc., as original issuer (“Guaranty”), and Wilmington Trust, National Association, as paying agent and co-registrar (“Wilmington”), as supplemented by that certain First Supplemental to Additional Paying Agent and Co-Registrar Agreement and Note, dated as of April 1, 2022, by and between Wilmington, the Company, as successor issuer, and Guaranty, governing the Company’s 5.25% Fixed-to-Floating Rate Subordinated Notes due 2030 (the “2030 Notes”).

 

Pursuant to the 2030 Notice, the Company gave holders of the 2030 Notes notice that it intends to redeem all $20.0 million of the outstanding 2030 Notes on September 30, 2025 (the “2030 Note Redemption Date”) at a redemption price equal to 100% of the aggregate principal amount of the 2030 Notes, plus accrued and unpaid interest thereon to, but excluding, the 2030 Note Redemption Date, in an aggregate amount of $20,522,083.

 

Redemption of 5.125% Fixed-to-Floating Rate Subordinated Notes due 2030

 

On July 25, 2025, the Company issued a notice of full redemption (the “MW Notice”) under that certain Subordinated Note Purchase Agreement, dated as of September 14, 2020, by and between the Company and Modern Woodmen of America (“MW”), governing the Company’s 5.125% Fixed-to-Floating Rate Subordinated Note due 2030 (the “MW Note”).

 

Pursuant to the MW Notice, the Company gave MW notice that it intends to redeem all $50.0 million of the outstanding MW Note on September 15, 2025 (the “MW Note Redemption Date”) at a redemption price equal to 100% of the aggregate principal amount of the MW Note, plus accrued and unpaid interest thereon to, but excluding, the MW Note Redemption Date, in an aggregate amount of $50,633,507.

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits.

 

104Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  QCR Holdings, Inc.
     
Date: July 25, 2025 By:  /s/ Todd A. Gipple
    Todd A. Gipple
    President and Chief Executive Officer

 

 

FAQ

What is N2OFF (NITO) asking shareholders to approve?

Four proposals: the MitoCareX acquisition, a 1-for-2 to 1-for-150 reverse split, 1.85 m warrant shares, and potential meeting adjournment.

How much dilution will current NITO shareholders face?

≈40% at closing and up to ≈25% more on milestone achievement, plus 1.85 m warrant shares.

Why is a reverse stock split proposed?

To give the board flexibility to cure potential Nasdaq bid-price deficiencies and manage share count after dilution.

How is MitoCareX being valued in the deal?

Through equity equal to 40% of NITO plus cash and earn-outs; no cash revenue metrics were disclosed.

When will the special meeting take place?

At 4:00 p.m. Israel time (9:00 a.m. EDT) on a date in 2025 to be specified in the final proxy materials.

What funding commitments has N2OFF made to MitoCareX?

An initial $1 m (less prior loans) at closing and additional R&D funding subject to board approval and resources.
Qcr Holdings

NASDAQ:QCRH

QCRH Rankings

QCRH Latest News

QCRH Latest SEC Filings

QCRH Stock Data

1.27B
16.33M
3.54%
75.25%
0.83%
Banks - Regional
State Commercial Banks
Link
United States
MOLINE